Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?

Lancet Oncol. 2010 Apr;11(4):312-3. doi: 10.1016/S1470-2045(10)70035-8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacology
  • Biomarkers
  • Cetuximab
  • Combined Modality Therapy
  • Cyclin-Dependent Kinase Inhibitor p16
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / radiotherapy
  • Head and Neck Neoplasms / therapy*
  • Head and Neck Neoplasms / virology*
  • Humans
  • Male
  • Neoplasm Proteins
  • Papillomavirus Infections / complications*
  • Patient Selection*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers
  • CDKN2A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • Neoplasm Proteins
  • Cetuximab